Skip to content

Triptolide preserves cognitive function and reduces hippocampal inflammation in a mouse model of Alzheimer's disease.

Sep 2026 · Molecular and cellular neurosciences · pp. 104126 · 0 citations · 23 references
Medicine

TL;DR

Results suggest that T10 improves learning and cognitive performance and reduces hippocampal inflammatory responses in 5xFAD mice, supporting its further investigation as a potential therapeutic intervention for AD.

Abstract

Alzheimer's disease (AD) is a prevalent neurodegenerative disorder that affects an estimated 50 million people worldwide. This remains a significant medical challenge. Despite the availability of numerous therapeutic agents, they are often only partially effective, highlighting the urgent need for the development of more effective next-generation drugs. Triptolide (T10), a key bioactive compound found in traditional Chinese medicine, is renowned for its wide range of pharmacological properties, including promising neuroprotective effects observed in vitro. However, its therapeutic effects and underlying mechanisms in the 5xFAD mouse model, particularly regarding microglial-mediated neuroinflammation, remain incompletely characterized. This study explored the impact of peripherally administered T10 on AD-associated behaviors and neuroinflammation in 5xFAD mice. The findings indicate that a 45-day T10 regimen significantly improved cognitive impairment in mice. Immunohistochemical analyses further demonstrated that T10 treatment markedly decreased Iba1-positive cell density in the CA1 region of the hippocampus and reduced immune and inflammatory responses in this region. Transcriptomic profiling suggests that T10 modulates cognitive function in 5xFAD mice via inflammatory signaling pathways. Taken together, these results suggest that T10 improves learning and cognitive performance and reduces hippocampal inflammatory responses in 5xFAD mice, supporting its further investigation as a potential therapeutic intervention for AD.

View source

Similar papers

Open access Sep 2026

Erinacine C Attenuates Alzheimer’s-like Pathology: A Study in APP/PS1 Mice and PC12 Cells

Investigation of the neuroprotective potential and associated signaling alterations of erinacine C using APP/PS1 transgenic mice and Aβ25-35-induced PC12 cells suggest that EC may mitigate cognitive impairment and neurodegeneration in parallel with alterations in the Akt/GSK3β/tau/caspase-3 signaling response.

Li-Yu Wang, Shu-Lan Yeh, Shih-Tien Hsu et al. · 0 citations
Open access Oct 2026

Fraxetin Ameliorates Cognitive Impairment in STZ-Induced Mice: Involvement of Suppressed Microglial Hyperactivation and Improved Mitochondrial Dysfunction

Therapeutic for Alzheimer’s disease (AD) remains a pressing medical challenge in the field of neuroscience. Natural compounds with structural diversity and multi-target regulatory properties have attracted increasing attention for the treatment of complex neurodegenerative disorders. Fraxetin, previously identified thr...

Jun Zhao, Yi-Ming Bai, Chao Wang et al. · 0 citations
Review Open access Sep 2026

The Role of Curcumin in Neurogenesis and Neuroprotection in Alzheimer’s disease: From Molecular Mechanisms to Clinical Evidence

This review discusses multi-target neuroprotective mechanisms of curcumin, critically reviews the preclinical success and human clinical trial outcomes, and highlights advanced nano formulations (solid lipid nanoparticles, colloidal sub-micron dispersions, polymeric nanoparticles, multi-walled carbon nanotubes and exos...

V. S, Sarupruthiya M, Jeevitha D et al. · 0 citations
Review Open access Sep 2026

The Role of Neuroinflammation in Alzheimer's Disease: Molecular Mechanisms and Emerging Therapeutic Approaches

This review examines the molecular and cellular mechanisms through which neuroinflammation contributes to the progression of AD, with particular emphasis on microglial activation, TREM2 and soluble TREM2 (sTREM2) signaling, NLRP3 inflammasome activation, astrocyte–microglia interactions, and blood–brain barrier dysfunc...

Shreyansh Goswami · 0 citations
Review Aug 2026

Neuropharmacological Interventions in Alzheimer’s Disease: Current and Emerging Approaches

Current preclinical and emerging evidence indicate that the modulation of interconnected pathological pathways, including mitochondrial dysfunction, insulin resistance, and neuroinflammation, may lead to improved therapeutic outcomes, and the incorporation of early diagnostic biomarkers in conjunction with the use of m...

Lalit Parihar, A. Singh, Sanjar Alam · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.